Is NCT04561206 recruiting in Duarte, CA?

Yes, NCT04561206 is currently recruiting participants at its Duarte, CA location. This hodgkin lymphoma clinical trial is actively enrolling qualified participants.

How do I join the hodgkin lymphoma clinical trial in Duarte?

To join this clinical trial in Duarte, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Duarte clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Hodgkin Lymphoma Clinical Trial in Duarte, CA

About This Hodgkin Lymphoma Study in Duarte

This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune sys

Sponsor: City of Hope Medical Center

Who Can Participate

Inclusion Criteria

Documented informed consent of the participant and/or legally authorized representative

Assent, when appropriate, will be obtained per institutional guidelines

Be willing to provide tissue (either from a fresh core or excisional biopsy performed as standard of care, or from archival tissue) of a biopsy that was performed after frontline systemic therapy, and prior to starting protocol therapy

If unavailable, exceptions may be granted with study principal investigator (PI) approval

Eastern Cooperative Oncology Group (ECOG) =\< 2

Histologically confirmed diagnosis of classical Hodgkin lymphoma (excluding nodular lymphocyte predominant Hodgkin lymphoma) according to the World Health Organization (WHO) classification, with hematopathology review at the participating institution

Relapsed or refractory disease after no more than 1 line of prior therapy (not counting radiotherapy). However, a maximum of 5 patients with primary refractory disease may be enrolled in this study. Note: Patients who received BV or an anti-PD-1/PD-L1 agent as part of frontline therapy are eligible if they achieved a CMR with frontline therapy and have not relapsed within 6 months from the end of frontline therapy Relapse must have been confirmed histologically (with hematopathology review at the participating institution)

Not a candidate for ASCT, based on age, co-morbidities, or patient preference. The reason for ASCT non-candidacy must be documented in the Case Report Form and verified by the site PI

Measurable disease (at least one non-bony fludeoxyglucose F-18 \[FDG\]-avid lesion \>= 1.5 cm in long axis)

Absolute neutrophil count (ANC) \>= 1,000/mm\^3

NOTE: Growth factor is not permitted within 7 days of ANC assessment unless cytopenia is secondary to disease involvement

Platelets \>= 50,000/mm\^3

NOTE: Platelet transfusions are not permitted within 7 days of platelet assessment unless cytopenia is secondary to disease involvement

Hemoglobin \>= 8 g/dL (no transfusion allowed within 3 days prior to screening)

Total bilirubin =\< 1.5 x upper limit of normal (ULN) or direct bilirubin =\< 1.5 x ULN for patients with Gilbert's disease

Aspartate aminotransferase (AST) =\< 2.5 x ULN

Alanine aminotransferase (ALT) =\< 2.5 x ULN

Creatinine clearance of \>= 40 mL/min per 24 hour urine test or the Cockcroft-Gault formula

Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Agreement by women and men of childbearing potential\

to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 5 months (women) or 7 months (men) after the last dose of protocol therapy

Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)

Exclusion Criteria

Concomitant investigational therapy

Live vaccine within 30 days prior to day 1 of protocol therapy (e.g. measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette-Guerin \[BCG\], oral polio vaccine, and oral typhoid)

Grade \>= 2 peripheral neuropathy

History of prior \>= grade 3 hypersensitivity to either brentuximab vedotin or nivolumab

Known active central nervous system (CNS) involvement by lymphoma, including parenchymal and/or lymphomatous meningitis

History of another primary malignancy that has not been in remission for at least 3 years, with the following exceptions:

Non-melanoma skin cancer treated with curative intent

In situ cervical cancer

If the malignancy is expected to not require any treatment for at least 2 years (this exception should be discussed with the study PI)

Condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration. Exceptions are:

Inhaled or topical steroids and

Adrenal replacement doses \> 10 mg daily prednisone equivalents in the absence of active autoimmune disease

History of progressive multifocal leukoencephalopathy (PML)

Prior diagnosis of inherited or acquired immunodeficiency

Active pneumonitis or interstitial lung disease

Active, known or suspected autoimmune disease. The following are exceptions:

Psoriasis not requiring systemic treatment

Hemolytic anemia associated with the lymphoma

Type I diabetes mellitus, if adequately controlled with therapy

Thyroid disease, if adequately controlled with therapy

Conditions not expected to recur in the absence of an external trigger (such exceptions should be discussed with the study PI)

Active history of:

Hepatitis B (hepatitis B virus \[HBV\]) or C (hepatitis C virus \[HCV\]) infection. Patients with past HBV infection (defined as negative hepatitis B surface antigen \[HBsAg\] and positive hepatitis B core antibody \[HBcAb\]) are eligible if HBV DNA is undetectable. Patients who are positive for HCV antibody are eligible if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)

Human immunodeficiency virus (HIV) infection. Subjects who have an undetectable or unquantifiable human immunodeficiency virus (HIV) viral load with CD4 \>= 200 and are on highly active antiretroviral therapy (HAART) medication are allowed. Testing to be done only in patients suspected of having infections or exposures

History of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association class III-IV within 6 months prior to day 1 of protocol therapy

Pregnant or breastfeeding

Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures

Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Duarte?

Yes, this clinical trial (NCT04561206) has an active research site in Duarte, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hodgkin Lymphoma Treatment Options in Duarte, CA

If you're searching for hodgkin lymphoma treatment options in Duarte, CA, this clinical trial (NCT04561206) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Duarte research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced hodgkin lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hodgkin lymphoma clinical trials near you to find additional studies recruiting in your area.

Hodgkin Lymphoma Clinical Trial in Duarte, CA

Expert Care in Duarte

IRB Approved

No-Cost Care

Apply for This Duarte Location

Why Participate?

Simple Process